DXB logo

Dimerix Limited Stock Price

ASX:DXB Community·AU$288.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

DXB Share Price Performance

AU$0.48
0.10 (28.00%)
AU$0.48
0.10 (28.00%)
Price AU$0.48

DXB Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks
1 Reward

Dimerix Limited Key Details

AU$5.6m

Revenue

AU$0

Cost of Revenue

AU$5.6m

Gross Profit

AU$18.8m

Other Expenses

-AU$13.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.022
100.00%
-237.20%
0%
View Full Analysis

About DXB

Founded
n/a
Employees
n/a
CEO
Nina Webster
WebsiteView website
dimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Recent DXB News & Updates

Recent updates

No updates